StreetAlpha.app
Home › Stocks › CMPX

Compass Therapeutics, Inc. (CMPX)

Healthcare
$0.69
▲ +1.43%
LAST CLOSE · NOV 20

Compass Therapeutics is a Boston biopharmaceutical company developing antibody drugs to treat cancer. It last closed at $0.69 on Nov 20, up 1.43% on the day. The next earnings report for CMPX is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, CMPX reported EPS of -$0.15. Over its last 8 reports the stock moved an average of 5.8% the session after earnings. Over the last 12 months CMPX insiders bought $27K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is CMPX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CMPX.

Key Stats

Last 12 months
Results
Net income
−$86.4M
EPS (diluted)
−$0.46
Free cash flow
−$61.9M
Valuation
Market cap
$123.9M
180.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.5M
At Sep 30
Shareholder equity
$142.6M
Shares outstanding
180.1M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $850K$850KFY2024FY2025: $0$0FY2025

From CMPX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · Time not announced
Reported EPS
-$0.15
Quarter ended Sep 2026
Year ago EPS
-$0.08
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.11Dec '24Mar 2025: -$0.12Mar '25Jun 2025: -$0.14Jun '25Sep 2025: -$0.08Sep '25Dec 2025: -$0.08Dec '25Mar 2026: -$0.10Mar '26Jun 2026: -$0.13Jun '26Sep 2026: -$0.15Sep '26Latest -$0.15
Revenue by quarter
Dec 2024: $0Dec '24Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Latest $0
How CMPX moved after its last 8 reports
Average move the session after a report ±5.8%
Nov 9, 2026Time not announced+10.3%
Aug 6, 2026Time not announced+5.3%
May 5, 2026Time not announced+0.5%
Mar 5, 2026Time not announced−2.8%
Jan 6, 2026Time not announced−1.6%
Nov 5, 2025Time not announced+0.8%
Aug 11, 2025Time not announced+23.7%
May 8, 2025Time not announced+1.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CMPXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CMPX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CMPX

Technical Analysis

CMPX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 8% below its 20 day and 43% below its 50 day average. It is 305% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 37), near oversold. The nearest support is the swing low (Nov 6) at $0.67, and the nearest resistance the Pivot at $0.69.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNear oversold
VolatilityHigh, 10.7%/day
Key levels
$6.8852 week high+897.1%
$2.78200 day average+302.9%
$1.60100 day average+131.9%
$0.9850 day average+42.0%
$0.81Swing high (Nov 2)+17.4%
$0.7420 day average+7.2%
$0.73Pivot R1+5.8%
$0.69Pivot+0.0%
$0.69Last close
$0.67Swing low (Nov 6)−2.9%
$0.64Pivot S1−7.2%
$0.5752 week low−17.4%
Indicators
RSI (14)37.29Weak, oversold below 30Neutral
MACD-0.09Above its signal lineBullish
Stochastic27.4Middle of its rangeNeutral
ADX (14)44.5Strong downtrend
Williams %R-63.7Oversold below −80, overbought above −20Neutral
CCI (20)-78.5Oversold below −100, overbought above 100Neutral
Rate of change−9.3%Change over 10 sessionsBearish
ATR (14)$0.07Typical daily range, 10.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CMPX

What happened before

See how CMPX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CMPX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CMPX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CMPXHow many large options trades hit CMPX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CMPX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼67 buying vs 140 selling
  • ▼Held by funds -2.8 pts
  • ▼Funds holding -44
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding173217−20.3%
In funds' top 10110.0%
Held by funds89.2%92.0%−2.8 pts
New / increased20 / 4763 / 85−54.7%
Reduced / sold out78 / 6244 / 48+52.2%
Put/call ratio0.420.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CMPX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CMPX Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$27K3 buys · 1 insider
Sold$00 sales · 0 insiders
2026-09 bought $3K2026-10 bought $18K2026-11 bought $6KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Neil LernerChief Accounting OfficerBuy10,000$0.59$6K
Oct 1Neil LernerChief Accounting OfficerBuy20,000$0.92$18K
Sep 24Neil LernerChief Accounting OfficerBuy2,500$1.14$3K
May 27, 2025Thomas J. SchuetzCEOBuy10,000$2.11$21K
Apr 9, 2025OrbiMed Capital GP VI LLCDirectorSale3,571,428$1.59$5.7M
Apr 9, 2025Carl L GordonDirectorSale3,571,428$1.59$5.7M
Every insider buy and sale for CMPX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CMPX insider trades →

From SEC Form 4 filings by CMPX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CMPX is in one of them and how their past CMPX trades turned out.

CMPX in the AI portfolios
Loading…

CMPX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CMPX in an article yet. Here's the latest on the wider market.

CMPX in the news

About Compass Therapeutics

Compass Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that develops antibody drugs for cancer. Its lead candidate, tovecimig, is designed to block two signaling pathways that tumors use to grow new blood vessels, and it is being tested in patients with biliary tract cancer. The company also has three other clinical stage candidates that target immune system pathways, including CD137 and PD-1. None of these candidates has been approved for sale.

Headquarters
Boston, MA